Seabrook v. Janssen Pharmaceuticals Inc.

CourtDistrict Court, S.D. New York
DecidedApril 19, 2021
Docket1:20-cv-02005
StatusUnknown

This text of Seabrook v. Janssen Pharmaceuticals Inc. (Seabrook v. Janssen Pharmaceuticals Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Seabrook v. Janssen Pharmaceuticals Inc., (S.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK JAMES SEABROOK, Plaintiff, 20-CV-2005 (LTS) -against- ORDERTO AMEND JANSSEN PHARMACEUTICALS, et al., Defendants. LAURA TAYLOR SWAIN, Chief United States District Judge: Plaintiff, currently incarcerated on Rikers Island, brings this pro se action under 42 U.S.C. § 1983, alleging that Defendants violated his rights by failing to warn him of the risks associated with the medication, Zyprexa,and then by denying him medical attentionfor conditions he developed after taking the drug. By order datedMarch 16, 2021, the Court granted Plaintiff’s request to proceed without prepayment of fees, that is, in forma pauperis (IFP).1 For the reasons set forth below, the Court grants Plaintiff leave to file an amended complaint within sixty days of the date of this order.2 STANDARD OF REVIEW The Prison Litigation Reform Act requires that federal courts screen complaints brought by prisoners who seek relief against a governmental entity or an officer or employee of a governmental entity. See28 U.S.C. § 1915A(a).The Court must dismiss a prisoner’s IFP

1 Prisoners are not exempt from paying the full filing fee even when they have been granted permission to proceed IFP. See 28 U.S.C. § 1915(b)(1). 2The Court had originally dismissed this actionbecause Plaintiff failed to pay the filing fee or submit an IFP application.After Plaintiff filed a motion for an extension of time to file a notice of appeal, the Court construed the motion as a motion to reopen the action, granted the motion,and directed Plaintiff to pay the filing fee or submit an IFP application. Plaintiff filed an IFP application,whichthe Court granted. complaint, or any portion of the complaint, that is frivolous or malicious, fails to state a claim upon which relief may be granted, or seeks monetary relief from a defendant who is immune from such relief. 28 U.S.C. §§ 1915(e)(2)(B), 1915A(b); seeAbbas v. Dixon, 480 F.3d 636, 639 (2d Cir. 2007).The Court must also dismiss a complaint if the court lacks subject matter jurisdiction. See Fed. R. Civ. P. 12(h)(3).

While the law mandates dismissal on any of these grounds, the Court is obliged to construe pro se pleadings liberally, Harris v. Mills, 572 F.3d 66, 72 (2d Cir. 2009), and interpret them to raise the “strongest [claims] that they suggest,” Triestman v. Fed. Bureau of Prisons, 470 F.3d 471, 474 (2d Cir. 2006) (internal quotation marks and citations omitted) (emphasis in original). But the “special solicitude”in pro se cases,id.at 475(citation omitted), has its limits – to state a claim,pro se pleadings still must comply with Rule 8 of the Federal Rules of Civil Procedure, which requires a complaint to make a short and plain statement showing that the pleader is entitled to relief. The Supreme Court has held that under Rule 8, a complaint must include enough facts to

state a claim for relief “that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). Aclaim is facially plausible if the plaintiff pleads enough factual detail to allow the Court to draw the inference that the defendant is liable for the alleged misconduct. In reviewing the complaint, the Court must accept all well-pleaded factual allegations as true. Ashcroft v. Iqbal, 556 U.S. 662, 678-79 (2009). But it does not have to accept as true “[t]hreadbare recitals of the elements of a cause of action,” which are essentially just legal conclusions. Twombly, 550 U.S.at 555.After separating legal conclusions from well-pleaded factual allegations, the Court must determine whether those facts make it plausible –not merely possible –that the pleader is entitled to relief.Id. BACKGROUND Plaintiff seeks money damages for Defendants’ alleged failure to warn his Manhattan Detention Center(MDC) doctors about the risks associated with taking the medication Zyprexa. He also seeks damages for the subsequent failure of the New York City Department of Correction (DOC) to provide adequate medical attention. Plaintiff names as Defendants:

(1) Janssen Pharmaceuticals Inc., (2) Janssen Research & Development LLC, and (3) Johnson & Johnson,the entities that allegedly failed to warn of Zyprexa’s risks(“Johnson & Johnson Defendants”); (4) Michael Latunji, an MDC endocrinologist; (5) Bessie Flores-Clemente,an MDC “appointment provider”; (6) Natasha Myles, a “plastic surgery ambcare” from Bellevue Hospital Center (Bellevue); (7) Jacques Hacquebord, an endocrinologist at Bellevue; and (8) Excerpta Media Inc.,which Plaintiff does not otherwise identify. Plaintiff alleges the following facts in his complaint, which is not a model of clarity: during an unspecified period of time, while Plaintiff was detained at the MDC,MDC medical staff prescribed Zyprexa to Plaintiff. Defendant “Janssen [had] directed its inadequate warning to [Plaintiff’s] doctors and failed to disclose Zyprexa[’s] actual risk.” (ECF 1, at 4.) Plaintiff now

“challeng[es] Janssen’s [illegible] defense given that Zyprexa was not an approved drug with respect to [his] condition.” (Id.) Plaintiff contends that as a result of taking Zyprexa, he developed a mass in his breastandseeks surgery because the mass is painful. Plaintiff also alleges that while in the custody of DOC, he has been“prejudged because of [his] physical appearance andsubjectedto improperly conducted strip searches.” (Id.at 5.)As for the allegation that he suffers pain in his breast, Plaintiff alleges that he “ha[s] been given noting but ibuprofen.” (Id.) DISCUSSION A. Federal Claims Against DOC Defendants Medical Claims Because Plaintiff alleges that correctional staff failed to treat his medical conditions, the Court construes the complaint as asserting medical claims under 42 U.S.C. § 1983. To state a claim under § 1983, Plaintiff must allege both that: (1) a right secured by the Constitution or laws of the United States was violated, and (2) the right was violated by a person acting under

the color of state law, or a “state actor.” West v. Atkins, 487 U.S. 42, 48-49 (1988).Here, Plaintiff’s claims arise under the Due Process Clause of the Fourteenth Amendment because Plaintiff was a pretrial detainee when correctional staff allegedly denied him medical care. Bell v. Wolfish, 441 U.S. 520, 536 n.16 (1979); Darnell v. Pineiro, 849 F.3d 17, 29 (2d Cir. 2017).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hertz Corp. v. Friend
559 U.S. 77 (Supreme Court, 2010)
Bell v. Wolfish
441 U.S. 520 (Supreme Court, 1979)
Daniels v. Williams
474 U.S. 327 (Supreme Court, 1986)
Davidson v. Cannon
474 U.S. 344 (Supreme Court, 1986)
West v. Atkins
487 U.S. 42 (Supreme Court, 1988)
Wisconsin Department of Corrections v. Schacht
524 U.S. 381 (Supreme Court, 1998)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
John Anthony Housand v. Maxwell Heiman
594 F.2d 923 (Second Circuit, 1979)
Walker v. Schult
717 F.3d 119 (Second Circuit, 2013)
Harris v. Mills
572 F.3d 66 (Second Circuit, 2009)
Blumatte v. Quinn
521 F. Supp. 2d 308 (S.D. New York, 2007)
Darnell v. City of New York
849 F.3d 17 (Second Circuit, 2017)
McCarthy v. Olin Corp.
119 F.3d 148 (Second Circuit, 1997)
Chance v. Armstrong
143 F.3d 698 (Second Circuit, 1998)
Bee v. Novartis Pharmaceuticals Corp.
18 F. Supp. 3d 268 (E.D. New York, 2014)
Harris v. Miller
818 F.3d 49 (Second Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Seabrook v. Janssen Pharmaceuticals Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/seabrook-v-janssen-pharmaceuticals-inc-nysd-2021.